Retatrutide.
Triple GLP-1/GIP/glucagon agonist — under clinical investigation for advanced metabolic protocols.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About Retatrutide.
Retatrutide is a triple agonist of the GLP-1, GIP and glucagon receptors. Phase 2 data published in 2023 showed weight loss exceeding any previously published GLP-1-class result. Phase 3 trials are ongoing.
Retatrutide does not yet hold a Marketing Authorisation. Magistral compounding requires individual physician judgement — the evidence base is more recent and the safety database smaller than for Semaglutide or Tirzepatide.
Triple agonism. GLP-1 receptor activation drives appetite suppression and glycemic control; GIP receptor activation modulates β-cell function and adipose handling; glucagon receptor activation increases energy expenditure via thermogenic and hepatic lipolysis pathways. The combination drives weight loss faster than dual-agonist molecules.
Subcutaneous injection, once weekly. Slow titration over several months from a low starting dose (1–2 mg) to a maintenance dose typically in the 4–12 mg range, depending on tolerance and clinical response.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- 01Jastreboff AM, et al. — Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med · 2023 · doi: 10.1056/NEJMoa2301972
- INN / Name
- Retatrutide
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 5mg vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.